Abzena Introduces New GS Knockout Platforms

Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, has expanded its AbZelectPRO cell line development (CLD) platform with the launch of two next-generation Glutamine Synthetase (GS) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins. The addition of the new GS knockout cell lines aims to further enhance speed, scalability, and flexibility for biopharma customers.

Named AbZelectPRO-KO and AbZelectPRO-KO+, the new GS knockout platforms are available as a standalone CLD offering or as a fully integrated GMP program, with fully transparent pricing to IND with no royalty fees. This flexible offering will enable customers to select a CLD strategy that aligns with their project-specific goals, timeline, and budget.

Campbell Bunce, CSO of Abzena, said, “The addition of these new GS knockout cell lines to our AbZelectPRO CLD platform is a powerful combination that truly sets a new standard of excellence. We are thrilled to offer such a robust, scalable, and state-of-the-art offering to support our customers’ therapeutic antibodies and difficult-to-express proteins.”

Licensed from Revvity, both GS knockout CHOSOURCE expression systems have been integrated into the AbZelectPRO CLD workflow and paired with ProteoNic Bioscience’s 2G UNic next-generation vector technology. This unified approach has been proven to enhance productivity and flexibility, enabling biopharma customers to quickly transition from DNA to research cell banks (RCB) in 10 weeks, with high-performing titers of up to 10g/L.